We are delighted to announce that Eisai have joined the Milner Therapeutics Consortium, which now includes 8 pharma partners. Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan. Eisai’s corporate mission is defined as “giving first thought to patients and their families and to increasing the benefits health care provides,” also known as their human health care philosophy. They strive to realise the human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including oncology and neurology.
Dr Peter Atkinson (Director and Head of Open Innovation, Neurology Business Group) and Dr Andy Takle (Executive Director and Head of Hatfield Research Laboratories, Neurology Business Group) will join our Innovation Board. “Eisai is delighted to join the Milner Therapeutics Consortium and we look forward to exploring new research partnership opportunities through this network, as part of our External Innovation strategy” says Andy Takle. “We are excited to welcome Eisai to the Consortium and hope that our strong alignment of research areas will enable innovative partnerships for uncovering new targets” says our Director Tony Kouzarides.
